SCHEMBL7190072

SCHEMBL7190072

COc1c(Cl)cc(Br)c(OC)c1P(=O)(C(=O)c1ccccc1)C(=O)c1c(C)cc(C)c(C)c1C

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAS1R3 Q7RTX0 2/20 0.38
TAS1R1 Q7RTX1 2/20 0.38
TAS1R2 Q8TE23 2/20 0.38
POLB P06746 2/20 0.38
ALDH1A1 P00352 5/20 0.35
HPGD P15428 3/20 0.35
LMNA P02545 3/20 0.35
MEN1 O00255 1/20 0.35
HTT P42858 1/20 0.35
KMT2A Q03164 1/20 0.35
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
CYP2C19 P33261 1/20 0.34
KDM4E B2RXH2 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
ATM Q13315 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
MAPT P10636 2/20 0.33
DRD3 P35462 1/20 0.33
SIRT1 Q96EB6 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7175781 0.89 TAS1R3 (0.40) TAS1R3TAS1R1TAS1R2POLBALDH1A1
SCHEMBL7181816 0.88 ATM (0.41) ALDH1A1HPGDLMNAMEN1HTT
SCHEMBL7182929 0.88 TAS1R3 (0.43) TAS1R3TAS1R1TAS1R2POLBALDH1A1
SCHEMBL7189133 0.87 TAS1R3 (0.38) TAS1R3TAS1R1TAS1R2POLBALDH1A1
SCHEMBL7180967 0.86 TAS1R3 (0.41) TAS1R3TAS1R1TAS1R2POLBALDH1A1
SCHEMBL7187547 0.86 POLB (0.40) TAS1R3TAS1R1TAS1R2POLBALDH1A1
SCHEMBL7183212 0.85 HPGD (0.42) ALDH1A1HPGDLMNAMEN1KMT2A
SCHEMBL7174658 0.85 ATM (0.38) TAS1R3TAS1R1TAS1R2ALDH1A1HPGD
SCHEMBL7190080 0.84 POLB (0.41) TAS1R3TAS1R1TAS1R2POLBALDH1A1
SCHEMBL7175861 0.84 HPGD (0.41) POLBALDH1A1HPGDLMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 TAS1R3 2990/4885TAS1R1 3374/4885TAS1R2 3865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.